Suppr超能文献

2013年逆转录病毒与机会性感染会议:抗逆转录病毒疗法的进展

CROI 2013: Advances in antiretroviral therapy.

作者信息

Taylor Barbara S, Wilkin Timothy J, Shalev Noga, Hammer Scott M

机构信息

University of Texas Health Science Center, San Antonio, TX, USA.

出版信息

Top Antivir Med. 2013 Apr-May;21(2):75-89.

Abstract

The 20th Conference on Retroviruses and Opportunistic Infections (CROI) presented important highlights of advances in antiretroviral therapy. Investigators emphasized new approaches to finding a cure for HIV infection, with a special focus on an infant who received combination antiretroviral therapy at 30 hours of age and may have achieved a functional cure in the absence of continued antiretroviral therapy. Challenges and opportunities for sustainable antiretroviral therapy under the Patient Protection and Affordable Care Act (PPACA) were discussed, and investigators around the globe examined attrition through the cascade of care for HIV disease and its implications. Knowledge of barriers to antiretroviral therapy in resource-limited settings (RLSs) continues to expand, as do innovative strategies for improving antiretroviral therapy access and uptake in these settings. Encouraging results from expanded prevention of mother-to-child transmission programs, including option B+, were presented. Prevalence of transmitted (primary) drug resistance appears to be increasing in the United States, and new detection techniques may increase access to resistance testing in RLSs.

摘要

第20届逆转录病毒与机会性感染会议(CROI)展示了抗逆转录病毒疗法进展的重要亮点。研究人员强调了寻找治愈HIV感染的新方法,特别关注一名在30小时大时接受联合抗逆转录病毒疗法且在未持续接受抗逆转录病毒治疗的情况下可能实现了功能性治愈的婴儿。讨论了《患者保护与平价医疗法案》(PPACA)下可持续抗逆转录病毒疗法面临的挑战和机遇,全球的研究人员审视了HIV疾病治疗过程中的失访情况及其影响。资源有限地区(RLS)抗逆转录病毒疗法障碍的相关知识不断扩展,改善这些地区抗逆转录病毒疗法可及性和接受度的创新策略亦是如此。会上介绍了扩大预防母婴传播项目(包括B+方案)取得的鼓舞人心的成果。在美国,传播性(原发性)耐药的流行率似乎在上升,新的检测技术可能会增加资源有限地区进行耐药检测的机会。

相似文献

1
CROI 2013: Advances in antiretroviral therapy.
Top Antivir Med. 2013 Apr-May;21(2):75-89.
2
CROI 2014: Advances in antiretroviral therapy.
Top Antivir Med. 2014 May;22(2):616-31.
3
Advances in antiretroviral therapy.
Top Antivir Med. 2012 Jun-Jul;20(2):61-86.
4
CROI 2016: Advances in Antiretroviral Therapy.
Top Antivir Med. 2016 May-Jun;24(1):59-81.
5
Advances in antiretroviral therapy.
Top Antivir Med. 2011 May-Jun;19(2):69-97.
6
Advances in antiretroviral therapy.
Top HIV Med. 2010 Apr-May;18(2):66-92.
7
CROI 2019: advances in antiretroviral therapy.
Top Antivir Med. 2019 Apr;27(1):50-68.
8
CROI 2018: Advances in Antiretroviral Therapy.
Top Antivir Med. 2018 May;26(1):40-53.
9
Advances in antiretroviral therapy.
Top HIV Med. 2006 Mar-Apr;14(1):36-62.
10
CROI 2015: Advances in Antiretroviral Therapy.
Top Antivir Med. 2015 Mar-Apr;23(1):28-45.

引用本文的文献

本文引用的文献

1
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Nature. 2012 Jul 25;487(7408):482-5. doi: 10.1038/nature11286.
4
Vital signs: HIV prevention through care and treatment--United States.
MMWR Morb Mortal Wkly Rep. 2011 Dec 2;60(47):1618-23.
5
Prevention of HIV-1 infection with early antiretroviral therapy.
N Engl J Med. 2011 Aug 11;365(6):493-505. doi: 10.1056/NEJMoa1105243. Epub 2011 Jul 18.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验